Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.TO)

VRX.TO on Toronto Stock Exchange

19.99CAD
12:09pm EST
Change (% chg)

$0.04 (+0.20%)
Prev Close
$19.95
Open
$20.00
Day's High
$20.18
Day's Low
$19.75
Volume
633,997
Avg. Vol
1,260,429
52-wk High
$165.77
52-wk Low
$18.41

VRX.TO

Chart for VRX.TO

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment,... (more)

Overall

Beta: -0.13
Market Cap(Mil.): $5,145.72
Shares Outstanding(Mil.): 341.19
Dividend: --
Yield (%): --

Financials

  VRX.TO Industry Sector
P/E (TTM): -- 30.04 30.65
EPS (TTM): -6.48 -- --
ROI: -5.29 15.86 15.23
ROE: -42.94 16.96 16.56

Takeda's talks to acquire Valeant's Salix stall: sources

Takeda Pharmaceutical Co Ltd's negotiations to acquire Valeant Pharmaceuticals International Inc's Salix stomach-drug business have stalled over price disagreements, people familiar with the matter said on Wednesday.

Nov 30 2016

BRIEF-Valeant announces initiation of a primary care sales force for Xifaxan and Relistor

* Valeant announces the initiation of a primary care sales force for Xifaxan and Relistor

Nov 29 2016

Ex-Valeant executive, ex-pharmacy CEO charged for fraud scheme

NEW YORK A former Valeant Pharmaceuticals International Inc executive and the former CEO of mail order pharmacy Philidor Rx Services were arrested on Thursday on charges that they engaged in a multimillion-dollar fraud and kickback scheme.

Nov 17 2016

Ex-Valeant executive, ex-pharmacy CEO charged for fraud scheme

NEW YORK A former Valeant Pharmaceuticals International Inc executive and the former CEO of mail order pharmacy Philidor Rx Services were arrested on Thursday on charges that they engaged in a multimillion-dollar fraud and kickback scheme.

Nov 17 2016

BRIEF-Valeant comments on issued Philidor criminal charges

Nov 17 Valeant Pharmaceuticals International Inc :

Nov 17 2016

Valeant Pharmaceuticals receives bids for core assets - CEO

Nov 15 Valeant Pharmaceuticals Inc, a heavily indebted Canadian drugmaker trying to sell non-core assets, has received offers for some core businesses, Chief Executive Joe Papa said on Tuesday.

Nov 15 2016

Valeant may seek to clean up its name by changing it: Ackman

NEW YORK Valeant Pharmaceuticals International Plc , the drugmaker that became a poster child for high drug prices during the U.S. election season, may change its name to help boost its reputation, board member and top investor William Ackman told CNBC on Wednesday.

Nov 10 2016

UPDATE 1-Valeant may seek to clean up its name by changing it -Ackman

NEW YORK, Nov 10 Valeant Pharmaceuticals International Plc, the drugmaker that became a poster child for high drug prices during the U.S. election season, may change its name to help boost its reputation, board member and top investor William Ackman told CNBC on Wednesday.

Nov 10 2016

Valeant may seek to clean up its name by changing it -Ackman

NEW YORK, Nov 10 Valeant Pharmaceuticals International Plc, the drugmaker that became a poster child for high drug prices during the U.S. election season, may change its name to help boost its reputation, board member and top investor William Ackman told CNBC on Wednesday.

Nov 10 2016

Perrigo to review options for Multiple Sclerosis drug Tysabri

Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri.

Nov 10 2016

Competitors

Earnings vs. Estimates